newsfilter
← Latest News
GlobeNewswire·

Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

MARLBOROUGH, Mass. and FRANKFURT, Germany, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company, and NeraCare, a leading developer of laboratory tests for the prognosis